Sugi Predict

Sugi Predict / Compounds / SCHEMBL10239204

SCHEMBL10239204

SCHEMBL10239204

CC(C)(C)OC(=O)N[C@@H]1CCCC(=O)C1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.55
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CTSK P43235 2/20 0.48
▸ GAA P10253 2/20 0.47
▸ THRB P10828 1/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ EPHX2 P34913 1/20 0.42
▸ DRD2 P14416 2/20 0.40
▸ JAK3 P52333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21597571 1.00 BTK (0.55) BTKCA1CA2CTSKGAA
SCHEMBL132145 1.00 BTK (0.55) BTKCA1CA2CTSKGAA
SCHEMBL24874466 0.95 BTK (0.54) BTKCA1CA2CTSKGAA
SCHEMBL13735251 0.95 BTK (0.54) BTKCA1CA2CTSKGAA
SCHEMBL720530 0.90 CTSK (0.50) BTKCA1CA2CTSKGAA
SCHEMBL8320677 0.90 CTSK (0.50) BTKCA1CA2CTSKGAA
SCHEMBL720531 0.90 CTSK (0.50) BTKCA1CA2CTSKGAA
SCHEMBL8220153 0.89 BTK (0.54) BTKCA1CA2CTSKGAA
Ammonia Solution, Strong SCHEMBL28630271 0.86 BTK (0.51) BTKCA1CA2CTSKGAA
SCHEMBL570801 0.83 GAA (0.54) BTKCA1CA2CTSKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118879800-A Synthesis method of (R) -3-tert-butoxycarbonyl amino cyclohexanone 苏州弗莱明生物技术有限公司 2024-11-01 — — CN claimed
US-12503445-B2 Compounds and their use ASTRAZENECA AB (SE) 2025-12-23 — — US disclosed
EP-4644380-A1 PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2025-11-05 — — EP disclosed
EP-4628490-A2 NLRP3 INFLAMMASOME INHIBITORS Astrazeneca AB (SE) 2025-10-08 — — EP disclosed
EP-4363406-B1 NLRP3 INFLAMMASOME INHIBITORS ASTRAZENECA AB (SE) 2025-09-10 — — EP disclosed
US-20240383862-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2024-11-21 — — US disclosed
CN-118879800-A Synthesis method of (R) -3-tert-butoxycarbonyl amino cyclohexanone 苏州弗莱明生物技术有限公司 2024-11-01 — — CN disclosed
WO-2024140824-A1 PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-07-04 — — WO disclosed
CN-118119598-A Medicine for treating human tumor by eRF3a targeting protein degradation mechanism 苏州德亘生物医药有限公司 2024-05-31 — — CN disclosed
US-11970463-B2 Compounds and their use ASTRAZENECA AB (SE) 2024-04-30 — — US disclosed
US-9351965-B2 Indazole derivatives useful as ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-05-31 — — US disclosed
WO-2016058544-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2016-04-21 — — WO disclosed
WO-2016058544-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2016-04-21 — — WO disclosed
WO-2015154039-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-10-08 — — WO disclosed
WO-2015154039-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-10-08 — — WO disclosed
WO-2015058140-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-04-23 — — WO disclosed
WO-2015058140-A1 POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2015-04-23 — — WO disclosed
US-20130261125-A1 INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-10-03 — — US disclosed
US-20130261125-A1 INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-10-03 — — US disclosed
WO-2012087772-A1 INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS SCHERING CORPORATION (US) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383862-A1 COMPOUNDS AND THEIR USE NLRP3, PYCARD, NLRP1 BTK 1222/4885CA1 4559/4885CA2 3656/4885
US-20130261125-A1 INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS MAPK3, MAPK1, MAP3K1 BTK 349/4885CA1 4121/4885CA2 2999/4885
US-11970463-B2 Compounds and their use NLRP3, PYCARD, NLRP1 BTK 1222/4885CA1 4559/4885CA2 3656/4885
US-12503445-B2 Compounds and their use NLRP3, PYCARD, NLRP1 BTK 1222/4885CA1 4559/4885CA2 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.